Small cell carcinoma of the lung

Influence of age on treatment outcome

Elizabeth Poplin, B. Thompson, M. Whitacre, Joseph Aisner

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Two hundred twenty-three patients between 29 and 78 years of age with small cell cancer of the lung were studied in serial protocols at the University of Maryland Cancer Center from 1975 to 1982. Each of these patients received chemotherapy consisting of doxorubicin, cyclophosphamide, and etoposide. In this paper we explore age and its interaction with the patient's extent of disease as it relates to clinical outcome variables such as the achievement of a complete response (CR), survival times, and various measures of toxicity. Preliminary evidence is found to suggest that an age-extent of disease interaction affects both the probability of obtaining a CR and the length of survival. Patients of all ages can benefit from treatment of small cell carcinomas of the lung with CR as the treatment goal. However, increased toxicity and early death remain as barriers to successful treatment of the elderly.

Original languageEnglish (US)
Pages (from-to)291-296
Number of pages6
JournalCancer treatment reports
Volume71
Issue number3
StatePublished - Jan 1 1987
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Survival
Etoposide
Doxorubicin
Cyclophosphamide
Therapeutics
Drug Therapy
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{c00940f3e455493f9cf7bad77c3c4ec0,
title = "Small cell carcinoma of the lung: Influence of age on treatment outcome",
abstract = "Two hundred twenty-three patients between 29 and 78 years of age with small cell cancer of the lung were studied in serial protocols at the University of Maryland Cancer Center from 1975 to 1982. Each of these patients received chemotherapy consisting of doxorubicin, cyclophosphamide, and etoposide. In this paper we explore age and its interaction with the patient's extent of disease as it relates to clinical outcome variables such as the achievement of a complete response (CR), survival times, and various measures of toxicity. Preliminary evidence is found to suggest that an age-extent of disease interaction affects both the probability of obtaining a CR and the length of survival. Patients of all ages can benefit from treatment of small cell carcinomas of the lung with CR as the treatment goal. However, increased toxicity and early death remain as barriers to successful treatment of the elderly.",
author = "Elizabeth Poplin and B. Thompson and M. Whitacre and Joseph Aisner",
year = "1987",
month = "1",
day = "1",
language = "English (US)",
volume = "71",
pages = "291--296",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

Small cell carcinoma of the lung : Influence of age on treatment outcome. / Poplin, Elizabeth; Thompson, B.; Whitacre, M.; Aisner, Joseph.

In: Cancer treatment reports, Vol. 71, No. 3, 01.01.1987, p. 291-296.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Small cell carcinoma of the lung

T2 - Influence of age on treatment outcome

AU - Poplin, Elizabeth

AU - Thompson, B.

AU - Whitacre, M.

AU - Aisner, Joseph

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Two hundred twenty-three patients between 29 and 78 years of age with small cell cancer of the lung were studied in serial protocols at the University of Maryland Cancer Center from 1975 to 1982. Each of these patients received chemotherapy consisting of doxorubicin, cyclophosphamide, and etoposide. In this paper we explore age and its interaction with the patient's extent of disease as it relates to clinical outcome variables such as the achievement of a complete response (CR), survival times, and various measures of toxicity. Preliminary evidence is found to suggest that an age-extent of disease interaction affects both the probability of obtaining a CR and the length of survival. Patients of all ages can benefit from treatment of small cell carcinomas of the lung with CR as the treatment goal. However, increased toxicity and early death remain as barriers to successful treatment of the elderly.

AB - Two hundred twenty-three patients between 29 and 78 years of age with small cell cancer of the lung were studied in serial protocols at the University of Maryland Cancer Center from 1975 to 1982. Each of these patients received chemotherapy consisting of doxorubicin, cyclophosphamide, and etoposide. In this paper we explore age and its interaction with the patient's extent of disease as it relates to clinical outcome variables such as the achievement of a complete response (CR), survival times, and various measures of toxicity. Preliminary evidence is found to suggest that an age-extent of disease interaction affects both the probability of obtaining a CR and the length of survival. Patients of all ages can benefit from treatment of small cell carcinomas of the lung with CR as the treatment goal. However, increased toxicity and early death remain as barriers to successful treatment of the elderly.

UR - http://www.scopus.com/inward/record.url?scp=0023140069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023140069&partnerID=8YFLogxK

M3 - Article

VL - 71

SP - 291

EP - 296

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

ER -